Annual balance sheet for VeraDermics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Cash and Equivalents | |||
| Short Term Investments | |||
| Cash and Short Term Investments | 16.3 | 53.1 | 142 |
| Net Total Receivables | 0 | 1.38 | 1.25 |
| Prepaid Expenses | |||
| Total Other Current Assets | |||
| Total Current Assets | 17.6 | 55.5 | 152 |
| Net Property, Plant And Equipment | — | — | 0.125 |
| Total Assets | 17.6 | 55.5 | 153 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 3.05 | 4.72 | 9.15 |
| Long Term Debt | |||
| Total Long Term Debt | |||
| Total Debt | |||
| Total Other Liabilities | |||
| Total Liabilities | 3.84 | 4.72 | 9.16 |
| Redeemable Preferred Stock | |||
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Other Equity | |||
| Total Equity | 13.7 | 50.8 | 143 |
| Total Liabilities & Shareholders' Equity | 17.6 | 55.5 | 153 |
| Total Common Shares Outstanding |